Figure 6

ML385 enhanced the cytotoxic effects of oxaliplatin and lobaplatin on CRC cells. (A–B) ML385 combined with oxaliplatin or lobaplatin significantly decreased the viability of CRC cells. (C–F) Compared to oxaliplatin or lobaplatin alone, the ML385 combined with oxaliplatin or lobaplatin promoted CRC cell apoptosis.